Benitec Biopharma Limited

BNTC Healthcare Biotechnology

In the quarter to June 2026, EPS fell 11.3%, free cash flow grew 38.9% and total debt fell 46.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

8.11 0.35 −4.14%
Market cap
$295.1M
P/E
0.0×
Fwd P/E
−1.8×
Dividend yield
—
F-score
3/9
Altman Z
−66.02
Beneish M
11.02
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
46.95 67.69 56.82 34.00
Net Debt/EBITDA
9.62 14.10 13.60 12.48
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.08) (0.08) (0.09) (0.11)
Book value per Share
2.25 4.08 3.71 3.80
Free Cash Flow
(3.35) (3.79) (4.47) (5.02)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026